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Medical treatment of ascites in cirrhosis 
Alexander L. Gerbes 
Department of Medicine I1, Klinikum Grosshadern, University of Munich, Germany 
Medical treatment of cirrhotic ascites is essentially supportive, dictated by the patient's discomfort, impaired car- 
diovascular o  respiratory function and potential for infection. Treatment of'simple' ascites (moderate fluid accumula- 
tion, serum albumin > 3.5 g/dl, serum creatinine < 1.5 mg/di, no electrolyte disturbance) is implemented sequentially. 
Only 10% of patients respond to dietary sodium restriction and bed rest; most require pharmacotherapy consisting 
of spironolactone, which increases the proportion of responding patients to 65% and loop diuretics, which may pro- 
duce clinical improvement i  an additional 20% (85% in all); in the remaining 15% of refractory patients, use of novel 
adjunctive therapies may be attempted. Patients with tense ascites, impaired renal function and electrolyte distur- 
bances merit special consideration before diuretics are introduced. Spironolactone has long been a standard for the 
treatment of cirrhotic ascites because it directly antagonizes aldosterone. The loop diuretic most frequently added to 
spironolactone has been furosemide. However, there is preliminary evidence that torasemide may be more effective 
in some patients. Other investigational agents that may play a role in treatment of patients resistant to conventional 
drugs include ornipressin (a vasopressin analogue) and atrial natriuretic factor. 
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A brief overview of the pathophysiology of ascites 
formation in hepatic cirrhosis (1) can facilitate 
understanding both of the available therapeutic options 
and of the rationale for development of new therapeutic 
approaches. Traditionally, the initiating event of renal 
sodium and water retention in cirrhosis was considered 
to be ascites formation (underfilling hypothesis) or 
primary renal dysfunction due to a hepatorenal reflex 
(overflow hypothesis) (2). The alterations of systemic, 
splanchnic and renal haemodynamics, a  well as in- 
creases in circulating levels of substances that cause 
sodium retention (3-6), are compatible with a decrease 
in effective blood volume as suggested by the underfill- 
ing hypothesis. These alterations, however, precede 
ascites formation. The recently introduced vasodilation 
hypothesis (7) reconciles many aspects of the underfill- 
ing theory and the overflow theory; it proposes that 
peripheral arterial vasodilation is the initiating event 
leading to decreased effective blood volume and renal 
sodium retention (Table 1) and suggests that 
haemodynamic, hormonal and renal changes are 
augmented as liver disease becomes more severe. 
Peripheral arterial vasodilation leads to a decrease inef- 
fective arterial blood volume and, in compensation, i -
creases in circulating levels of renin, aldosterone, 
noradrenaline and vasopressin, which result in renal 
vasoconstriction with sodium and water etention. With 
increasing severity of cirrhosis, the activation of these 
stimulants of sodium retention cannot restore ffective 
blood volume. This, together with a decrease in plasma 
oncotic pressure due to hypoalbuminaemia and an in- 
crease in hydrostatic pressure in the splanchnic vessels, 
results in extravasation of fluid. Once the resorptive 
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TABLE 1 
Vasodilation hypothesis of ascites formation: Sequence of events 
1. Cirrhosis 
2. Peripheral arterial vasodilation 
3. Decrease in effective blood volume 
4. Activation of volume-retaining hormones 
5. Renal sodium retention 
6. Increase in blood volume 
7. Ascites 
transplantation. This article, concentrates on medical 
therapy for ascites which, like all procedures other than 
transplantation, is only supportive. Therefore, the prin- 
ciple of 'primum nil nocere' should always be kept in 
mind (11-13). 
Medical therapeutic options 
capacity of the lymphatic vessels is exceeded, ascites 
becomes overt. 
After the diagnosis of ascites is established by clinical 
examination and ultrasonography, the cause of the con- 
dition must be determined. The patient's medical history 
and results of typical aboratory assays can often reveal 
malignant causes (e.g. peritoneal carcinomatosis and 
liver metastasis) or non-malignant causes (e.g. cirrhosis 
of the liver). Laboratory examination of the ascitic fluid 
can be helpful in differentiating the cause of ascites 
(8-10), particularly determinations of cholesterol, car- 
cinoembryonic antigen and other tumour markers in ad- 
dition to cell count and differentiation; bacteriologic 
and cytologic examinations also play an important role 
in differential diagnosis (Fig. 1). 
Ascites does not require treatment merely because it
exists. However, most patients with ascites feel uncom- 
fortable and their physical ctivity is limited. Further- 
more, therapy for ascites is indicated by the impairment 
of cardiovascular nd respiratory functions due to tense 
ascites and the potential development of spontaneous 
bacterial peritonitis. Several therapeutic options are 
available for the management of ascites in patients with 
hepatic irrhosis: bed rest, restriction of sodium intake, 
diuretics, paracentesis, temporary or continuous reinfu- 
sion procedures (such as peritoneovenous shunting), 
portacaval or intrahepatic shunting procedures and liver 
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Fig. 1. Laboratory analyses of ascitic fluid and imaging techniques 
valuable in the differential diagnosis of ascites, fl-hCG, fl-human 
chorionic gonadotropin; CEA, carcinoembryonic antigen; CT, com- 
puted tomography. 
Sodium balance can be achieved more easily when 
sodium intake is restricted. Limitation to about 50 mmol 
of sodium, which corresponds to approximately 3 g of 
dietary salt, is usually well tolerated. Lower levels of 
sodium intake result in less palatable diets and thus lead 
to poorer patient compliance; severely restricted sodium 
intake may also contribute to increased activation of the 
renin-angiotensin-aldosterone system. Bed rest alone 
has a diuretic effect hat can augment the natriuresis in- 
duced by diuretic drugs (14-16). 
The results of randomised, controlled trials have 
disclosed the following about diuretictherapy: 
• Sodium excretion is induced by combination therapy 
with spironolactone and furosemide (17). 
• In the setting of cirrhosis, spironolactone alone or 
combined with furosemide induces greater sodium 
excretion than furosemide alone (18,19). 
• Restriction of salt and water intake alone is less effi- 
cient than salt and water restriction plus the use of 
spironolactone or the combination of spironolactone 
and furosemide (20). 
Based on these findings, sequential therapy for ascites is 
usually recommended (Fig. 2). 
Sequential approach to ascites management 
Sodium restriction and bed rest are sufficient to 
manage ascites in about 10% of patients. However, 
because an adequate response (mean reduction in body 
wt. ~ 400 g/day for 4 days) will not be seen in most pa- 
tients, administration ofspironolactone will be required. 
Ascites can be alleviated in approximately 65% of pa- 
tients with spironolactone, the mainstay of diuretic 
therapy for ascites, at dosages of up to 300 mg/day oral- 
ly. Addition of a loop diuretic (e.g. furosemide) at 
dosages of up to 120 rag/day orally increases the rate of 
therapeutic success to approximately 85%. In about 15% 
of patients, ascites remains refractory to diuretic therapy 
or treatment must be discontinued because of side 
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Fig. 2. Sequential approach toascites management in hepatic cirrhosis 
and rate of therapeutic success. 
effects, such as encephalopathy, hyponatraemia, 
hypokalaemia, or hyperkaemia. 
Guidelines for optimum benefit 
The patient with ascites should be thoroughly 
evaluated after treatment with a balanced sodium diet 
alone for at least 5 days. This clinical evaluation must 
include measurement of blood pressure and heart rate as 
well as examinations for encephalopathy and muscular 
and neurologic abnormalities. At the same time, serum 
should be analysed for concentrations of sodium, 
potassium, creatinine, urea, calcium, magnesium, 
albumin and uric acid and serum osmolality should be 
assessed. Recommendations al o include weighing the 
patient dailyand analysing 24-h urine collections every 
other day. Urinalysis hould measure concentrations of 
sodium, potassium and creatinine, as well as urinary 
osmolality, which will allow for the calculation of 
creatinine clearance, fractional sodium excretion and 
the urinary sodium/potassium ratio. In addition, 
laboratory examination of the urinary sediment may in- 
dicate glomerular or tubular damage. After this initial 
evaluation, the patient may be classified as having 'sim- 
ple' or 'complex' ascites. 
Managing simple ascites 
Patients may be regarded as having simple ascites 
when there is no evidence of serum electrolyte abnor- 
malities, hypoalbuminaemia, or encephalopathy; no 
major reduction in glomerular filtration rate; no 
outstanding sodium retention; and no more than a 
moderate accumulation of ascitic fluid (Table 2). The 
condition of these patients will likely respond to the con- 
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TABLE 2 
Characteristics of 'simple' ascites uggesting sequential diuretic 
therapy 
Moderate degree of aseites 
No encephalopathy 
Urinary sodium excretion > 20 mmol/day 
Fractional sodium excretion >0.3% 
Levels of serum constituents 
Sodium > 130 mmol/l 
Potassium 3.6-4.9 mmol/l 
Albumin >3.5 g/dl 
Creatinine <1.5 mg/dl 
ventional sequential therapy of ascites. Spironolactone 
is the initial agent of choice rather than a loop diuretic 
because it directly antagonizes aldosterone, the pivotal 
hormone in oedematous disorders. Moreover, spirono- 
lactone treatment generally avoids the overly brisk 
diuresis, natriuresis and potassium loss associated with 
loop diuretics. 
If simple ascites does not respond adequately to 
diuretic therapy, several possibilities should be con- 
sidered. A lack of decrease in body weight, despite 
marked urinary sodium excretion, indicates a high 
sodium intake; this may be due to dietary non- 
compliance or to inadvertent iatrogenic sodium ad- 
ministration (e.g. antibiotics, antacids). Because amino 
acids increase glomerular filtration rate, a diet severely 
restricted in protein (e.g. to prevent encephalopathy) 
may impair renal function. In addition, renal function 
can be affected by use of cyclooxygenase inhibitors, 
typified by non-steroidal nti-inflammatory drugs such 
as indomethacin; by volume depletion resulting from 
lactulose-induced diarrhoea; and by overly vigorous 
diuresis. Furthermore, some drugs (e.g. aminoglyco- 
sides) may directly damage the renal tubule. In the 
absence of the preceding possibilities, a l ck of response 
to diuretic treatment might indicate fulminant hepatitis, 
spontaneous bacterial peritonitis or gastrointestinal 
bleeding. 
Managing complex ascites 
Whether complex ascites exists initially or develops 
during therapy, its management needs pecial attention. 
Hyponatraemia s largely caused by dilution and, 
therefore, should be managed with fluid restriction. 
Hypokalaemia demands potassium replacement or a 
modification of the diuretic regimen; the latter is also in- 
dicated in hyperkalaemia. Patients whose serum 
albumin concentration is <3.5 g/dl may benefit from 
the intravenous administration of salt-poor albumin 
(21), although the value of this intervention has not been 
clearly demonstrated by clinical studies. Spontaneous 
bacterial peritonitis must be managed with antibiotics. 
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Severe hepatic encephalopathy requires treatment (e.g. 
by stringent dietary protein limitation, lactulose ad- 
ministration and, possibly, consideration of liver 
transplantation. 
Tense ascites may be relieved initially by therapeutic 
paracentesis (22); an adequate diuretic dosage can then 
be established (23). Diuretic therapy should not routine- 
ly be started in patients whose serum creatinine concen- 
trations are > 2 mg/dl because of the risk of azotaemia 
and renal failure. 
Minimizing side sects 
Side effects of therapy for ascites may be minimized 
by monitoring urinary volume and electrolyte excretion 
and maintaining normal evels of serum electrolytes and 
renal function. Side effects may also be minimized by 
controlling body weight, blood pressure and heart rate. 
To avoid reducing the effective blood volume and fur- 
ther activating mechanisms of sodium retention in pa- 
tients without peripheral oedema, diuretic dosage 
should be adjusted to provide a daily weight loss of no 
more than 750-900 g. However, patients with peripheral 
oedema can tolerate a daily weight .loss of _> 1.5 kg 
without significant side effects (23,24). 
Investigational agents for use in refractory ascites 
In the minority of patients who fail to respond to 
conventional therapies, which are based on bed rest, 
sodium restriction and administration of spironolactone 
(up to'a maximum of 300 mg/day) and the subsequent 
addition of furosemide (up to a maximum of 120 
mg/day), three other agents currently under investiga- 
tion may be tried. One of them, torasemide, is a loop 
diuretic, while the other two, atrial natriuretic peptide 
(ANP) and ornipressin, act as hormones. 
Torasemide 
A now loop diuretic, torasemide, has a bioavailability 
of >85% (25). Compared with furosemide, torasemide 
has a longer half-life and smoother, more prolonged ac- 
tivity; these features may be advantageous for cirrhotic 
patients, who are sensitive to sudden decreases in in- 
travascular volume. 
A recent study found that in patients with ascites, 
torasemide induced aprolonged natriuresis and stronger 
diuresis than furosemide (26). Of particular interest, pa- 
tients whose ascites did not respond to administration f 
furosemide or to a combination of spironolactone and 
furosemide exhibited significantly greater natriuresis 
after receiving torasemide or the combination of 
spironolactone and torasemide, respectively (26,27). 
However, further investigation is needed to establish 
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torasemide asthe preferred loop diuretic in cirrhotic pa- 
tients with ascites. 
Atrial natriuretic factor (ANF) 
The potential therapeutic application of ANF (or its 
analogues) to patients with ascites has recently received 
attention (28,29) despite the fact that ANF must be ad- 
ministered intravenously and has a short duration of ac- 
tion. It increases glomerular filtration rate, influences 
tubuloglomerular feedback and decreases the release of 
renin; it also inhibits the synthesis and release of 
aldosterone (30). However, in animal models and pa- 
tients with cirrhosis, particularly those with ascites, the 
renal response to ANF seems to be blunted (31,32). This 
might be due to alterations in renal ANF receptors (33) 
as well as to a decrease in mean arterial pressure follow- 
ing ANF administration in cirrhotic subjects (34). Thus, 
low-dose infusions of ANF may induce greater 
natriuresis than high-dose infusions. 
Coadministration f vasoconstrictors might prevent 
ANF-induced hypotension. In an animal model of por- 
tal hypertension, combination with vasopressin was 
shown to potentiate he natriuresis and diuresis induced 
by ANF (35,36). Clinical evaluation of such combina- 
tion therapy has not yet been pursued. The development 
of inhibitors of the ANF-degrading prot'einase EC 
3.4.24.11 or of ANF analogues that selectively bind to 
clearance receptors (37) may result in a longer-acting 
oral agent, which could prompt clinical studies. 
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Fig. 3. Changes inrenal sodium excretion after 2- and 4-h infusions of 
ornipressin and 2 h after infusion termination (Lenz et al., 1991). 
Shading indicates normal ranges. FENa, fractional e imination of
sodium. 
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Ornipressin 
The effects of the vasopressin analogue ornipressin 
were recently studied in patients with poor renal func- 
tion who were treated in an intensive care unit (38). 
After 2-h and 4-h infusions, peripheral v sodilation and 
the renal vasoconstriction reversed in part and were 
accompanied by a decrease in activation of the 
mechanisms of sodium retention and an increase in 
circulating levels of ANF. These effects resulted in im- 
proved renal function and sodium excretion (Fig. 3). 
Ornipressin infusion thus may be helpful as a short-term 
intervention to improve the critical condition of such 
patients. 
Additional alternatives 
Other therapeutic approaches may prove useful, par- 
ticularly in patients whose ascites is resistant to c nven- 
tional diuretic therapy. The development of antagonists 
to block the increased synthesis of leukotrienes (39,40) 
and to attenuate he effects of platelet-activating factor 
(41,42) might be helpful, particularly for patients with 
renal impairment. 
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